Martin Stogniew
Transcend Engineering (United States)(US)
Publications by Year
Research Areas
Cancer therapeutics and mechanisms, Receptor Mechanisms and Signaling, PARP inhibition in cancer therapy, Glioma Diagnosis and Treatment, Neuroblastoma Research and Treatments
Most-Cited Works
- → Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality(2019)342 cited
- → A Bayesian machine learning approach for drug target identification using diverse data types(2019)250 cited
- → Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201(2019)189 cited
- → ONC201 and imipridones: Anti-cancer compounds with clinical efficacy(2020)163 cited
- → Discovery and clinical introduction of first-in-class imipridone ONC201(2016)161 cited
- → First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors(2017)153 cited
- → Anidulafungin Does Not Require Dosage Adjustment in Subjects With Varying Degrees of Hepatic or Renal Impairment(2007)112 cited
- → Assessment of the Safety and Pharmacokinetics of Anidulafungin When Administered With Cyclosporine(2005)106 cited
- → Biological activity of weekly ONC201 in adult recurrent glioblastoma patients(2019)88 cited
- → Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212(2017)79 cited